1
|
Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers 2024:3936155241239672. [PMID: 38613331 DOI: 10.1177/03936155241239672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/14/2024]
Abstract
Biobanks are valuable tools for developing and applying scientific research and international cooperation through the collection of biological materials and their associated data. Systematic research following the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines was conducted in late 2022 in PubMed and Scopus, and generated 17 articles to be reviewed in depth and critically assessed using the Critical Appraisal Skills Programme Checklist due to the limited available data; 12 relevant health organizations and government websites outside of peer-reviewed journals were also included. Our research identified 44 biobanks in Latin America. In general, there is a lack of regulation and legislation guaranteeing the stored materials' quality and institutional collaboration. We believe a consensus needs to be reached regarding the terminology and definitions used for biobanks. The design for informed consent should also be agreed upon to ensure the privacy of the data shared among institutions. In conclusion, in Latin America, there is a clear need for government support in creating specific procedures for biobanks and providing further support for existing biobanks.
Collapse
Affiliation(s)
| | | | - Gabriela A Galán-Ramírez
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Mexico City, Mexico
- Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Ivette Cruz-Bautista
- Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Roopa Mehta
- Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Carlos A Aguilar-Salinas
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Mexico City, Mexico
- Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Alexandro J Martagon
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Mexico City, Mexico
- Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- The Institute for Obesity Research, Tecnologico de Monterrey, Monterrey, Mexico
| |
Collapse
|
2
|
Parsons CLB, Mountain RV, Jacobsson K, Bidlack FB, Lehmann LS, Dunn EC. Cultural diversity of traditions for the disposal of exfoliated teeth: Implications for researchers. Community Dent Oral Epidemiol 2024; 52:139-149. [PMID: 38217075 DOI: 10.1111/cdoe.12928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 10/25/2023] [Accepted: 11/06/2023] [Indexed: 01/14/2024]
Abstract
OBJECTIVES For decades, researchers in anthropology and archaeology have used teeth, including exfoliated primary teeth, as fossil records of people's physical life experiences. Recently, researchers in psychiatry, epidemiology, environmental health and other fields have recognized the potential for teeth to serve as biomarkers of other early-life experiences, including trauma exposure and other types of psychosocial stress, which are potent determinants of later mental and physical health problems. Despite the emerging appreciation and value of teeth as biospecimens, little is understood about cultural beliefs and practices surrounding exfoliated teeth. If known, such insights could inform culturally appropriate practices for paediatric dental care and improve protocols for the ethical acquisition of teeth as biospecimens in research studies. To address this gap, a qualitative systematic review was performed to summarize the variety of traditions performed worldwide for disposing of primary exfoliated teeth. METHODS PubMed, Google Scholar, AnthroSource, Anthropological Literature, EHRAF World Cultures and Anthropology Plus were searched with a systematic search strategy to identify articles published from inception through December 2, 2021. Citations of relevant papers were also forward and backward searched. RESULTS There were 3289 articles that met the initial inclusion criteria, of which 37 were included after individual screening and applying exclusion criteria. Thematic analysis was used to identify 74 distinct traditions related to the disposal of exfoliated teeth, which were organized into seven general themes: (1) giving teeth to a tooth fairy, (2) giving teeth to mouse figures, (3) throwing teeth, (4) hiding/keeping teeth, (5) burying teeth, (6) giving teeth to animals and (7) eating the tooth. CONCLUSIONS The results of this study elucidate the diversity within-yet universality of-exfoliated tooth disposal traditions and underscore the importance of tooth exfoliation as a major milestone during child development. Special attention must be paid to these traditions and related ethical concerns when designing research protocols related to their collection. With a greater understanding of beliefs and practices related to exfoliated teeth, researchers will be better equipped to engage children and families in studies that include analyses of exfoliated teeth, collect teeth as biospecimens, and broaden the use of teeth in research.
Collapse
Affiliation(s)
- Clara L B Parsons
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Rebecca V Mountain
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Psychiatry, Harvard Medical School and the Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Kristina Jacobsson
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Felicitas B Bidlack
- Forsyth Institute, Cambridge, Massachusetts, USA
- Department of Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts, USA
| | - Lisa Soleymani Lehmann
- Brigham and Women's Division of General Internal Medicine and Primary Care, Department of Medicine, Boston, Massachusetts, USA
| | - Erin C Dunn
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Psychiatry, Harvard Medical School and the Massachusetts General Hospital, Boston, Massachusetts, USA
- Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Vitti JN, Vitti R, Chu K, Mellis S. The ethics of clinical research in the era of COVID-19. Front Public Health 2024; 12:1359654. [PMID: 38510356 PMCID: PMC10950982 DOI: 10.3389/fpubh.2024.1359654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 02/20/2024] [Indexed: 03/22/2024] Open
Abstract
There is an urgent need for increased understanding of COVID-19 and strategies for its prevention, treatment, and mitigation. All participants in the research enterprise, including institutional review boards, have an ethical duty to protect participants and ensure that the benefits gained from such research do not conflict with the core principles that guided researchers prior to the pandemic. In this review, we discuss the ethical issues surrounding initiation and conduct of clinical trials, focusing on novel COVID-19 therapeutic, vaccine, or biospecimen research, using the principles of autonomy, beneficence, and justice. We discuss strategies to manage the practical challenges associated with the conduct of clinical trials, with an emphasis on maintaining the rights and welfare of research participants.
Collapse
Affiliation(s)
| | - Robert Vitti
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States
| | - Karen Chu
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States
| | - Scott Mellis
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States
| |
Collapse
|
4
|
Vivelo C, Reilly KM, Widemann BC, Wedekind MF, Painter C, O'Neill AF, Mueller S, Elemento O, Gross AM, Sandler AB. The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. Oncologist 2024; 29:106-116. [PMID: 37878787 PMCID: PMC10836296 DOI: 10.1093/oncolo/oyad285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 09/23/2023] [Indexed: 10/27/2023] Open
Abstract
Rare cancers and other rare nonmalignant tumors comprise 25% of all cancer diagnoses and account for 25% of all cancer deaths. They are difficult to study due to many factors, including infrequent occurrence, lack of a universal infrastructure for data and/or tissue collection, and a paucity of disease models to test potential treatments. For each individual rare cancer, the limited number of diagnosed cases makes it difficult to recruit sufficient patients for clinical studies, and rare cancer research studies are often siloed. As a result, progress has been slow for many of these cancers. While rare cancer research efforts have increased over time, the breadth of the research landscape is not known. A recent literature search revealed a sharp increase in rare tumor, and rare cancer publications began in the early 2000s. To identify rare cancer research efforts being conducted in the US and globally, we conducted an online search of rare tumor/rare cancer research programs and identified 76 programs. To gain a deeper understanding of these programs, we composed and conducted a survey to ask programs for details about their research efforts. Of the 42 programs contacted to complete the survey, 23 programs responded. Survey results show most programs are collecting clinical data, molecular data, and biospecimens, and many are conducting molecular analyses. This landscape analysis demonstrates that multiple rare cancer research efforts are ongoing, and the rare cancer community may benefit from collaboration among stakeholders to accelerate research and improve patient outcomes.
Collapse
Affiliation(s)
- Christina Vivelo
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
- Kelly Government Systems, Bethesda, MD, USA
| | - Karlyne M Reilly
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Brigitte C Widemann
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Mary Frances Wedekind
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | | | - Allison F O'Neill
- Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders, Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA, USA
| | - Sabine Mueller
- Department of Neurology, Neurosurgery, and Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - Olivier Elemento
- Caryl and Israel Englander Institute for Precision Medicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
| | - Andrea M Gross
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Abby B Sandler
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| |
Collapse
|
5
|
Passmore SR, Gerbitz A, Hancock GR, Evans L, Green-Harris G, Edwards DF, Jackson T, Thomas SB. "My Blood, You Know, My Biology Being out There…": Consent and Participant Control of Biological Samples. J Empir Res Hum Res Ethics 2024; 19:3-15. [PMID: 38192107 PMCID: PMC10957312 DOI: 10.1177/15562646231222665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
The widespread and persistent underrepresentation of groups experiencing health disparities in research involving biospecimens is a barrier to scientific knowledge and advances in health equity. To ensure that all groups have the opportunity to participate in research and feel welcome and safe doing so, we must understand how research studies may be shaped to promote inclusion. In this study, we explored the decision to participate in hypothetical research scenarios among African American adults (n = 169) that varied on the basis of four attributes (form of consent, reason for research, institutional affiliation and race of the researcher). Findings indicate that participants were largely willing to contribute to biobanks but significantly preferred opportunities where they had control over the use of their biological samples through tiered or study-specific forms of consent. Broad consent procedures, although common and perhaps preferred by participants with high trust in researchers, may amount to an exclusionary practice.
Collapse
Affiliation(s)
| | - Abigail Gerbitz
- School of Nursing, University of Wisconsin, Madison, WI, USA
| | - Gregory R. Hancock
- Department of Human Development and Quantitative Methodology, College of Education, University of Maryland, College Park, MD, USA
| | - Laura Evans
- Human Development and Family Studies, School of Human Ecology, University of Wisconsin, Madison, WI, USA
| | - Gina Green-Harris
- Center for Community Engagement and Health Partnerships, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
- Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, USA
| | - Dorothy Farrar Edwards
- School of Nursing, University of Wisconsin, Madison, WI, USA
- Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, USA
- Department of Kinesiology, School of Education, University of Wisconsin, Madison, USA
| | - Tyson Jackson
- School of Nursing, University of Wisconsin, Madison, WI, USA
| | - Stephen B. Thomas
- Center for Health Equity, School of Public Health, University of Maryland, College Park, MD, USA
- Department of Health Policy and Management, School of Public Health, University of Maryland, College Park, MD, USA
| |
Collapse
|
6
|
Smith MZ, Turner M, Haurat J, Thevarajan I, Denholm J, Tong SYC, Matthews GV, Bull RA, Martinello M, McMahon J, Imrie A, Pillai PE. The APPRISE Virtual Biobank for Infectious Diseases. Commun Dis Intell (2018) 2023; 47. [PMID: 37968063 DOI: 10.33321/cdi.2023.47.66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Indexed: 11/17/2023]
Abstract
The Australian Partnership for Preparedness Research on InfectiouS disease Emergencies (APPRISE) has developed a virtual biobank to support infectious disease research in Australia. The virtual biobank (https://apprise.biogrid.org.au) integrates access to existing distributed infectious disease biospecimen collections comprising multiple specimen types, including plasma, serum, and peripheral blood mononuclear cells. Through the development of a common data model, multiple collections can be searched simultaneously via a secure web portal. The portal enhances the visibility and searchability of existing collections within their current governance and custodianship arrangements. The portal is easily scalable for integration of additional collections.
Collapse
Affiliation(s)
- Miranda Z Smith
- Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia .
| | - Maureen Turner
- BioGrid Australia, North Melbourne, Victoria 3051, Australia
| | - Javier Haurat
- BioGrid Australia, North Melbourne, Victoria 3051, Australia
| | - Irani Thevarajan
- 1. Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia ;St Vincent's Hospital, NSW, 2010, Australia
| | - Justin Denholm
- Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia
| | - Steven YC Tong
- Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia
| | - Gail V Matthews
- The Kirby Institute, UNSW Sydney, NSW, 2052 Australia; St Vincent's Hospital, NSW, 2010, Australia
| | - Rowena A Bull
- The Kirby Institute, UNSW Sydney, NSW, 2052 Australia; School of Medical Sciences, UNSW Sydney, NSW 2052, Australia
| | - Marianne Martinello
- The Kirby Institute, UNSW Sydney, NSW, 2052 Australia; Prince of Wales Hospital, Randwick, NSW, 2031, Australia
| | - James McMahon
- Monash Infectious Diseases, Monash Medical Centre, Monash Health, Victoria, 3168, Australia; Department of Infectious Diseases, Monash University and Alfred Hospital, Victoria, 3004, Australia
| | - Allison Imrie
- School of Biomedical Sciences, University of Western Australia, WA, 6009, Australia
| | - Priyanka E Pillai
- Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia; Melbourne Data Analytics Platform, University of Melbourne, Victoria, 3000, Australia
| |
Collapse
|
7
|
Policiuc L, Bica C, Ciocan C, Leucuta DC, Nutu A, Berindan-Neagoe I. Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens. Med Pharm Rep 2023; 96:392-399. [PMID: 37970200 PMCID: PMC10642746 DOI: 10.15386/mpr-2646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 06/13/2023] [Accepted: 07/03/2023] [Indexed: 11/17/2023] Open
Abstract
Background and aims In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of 'biobanking' and 'personalized medicine' in three categories of participants in the development of a biobank - health professionals (clinicians/diagnosticians), scientific researchers, and patients, in order to identify possible faults regarding the level of information. The secondary objective of this study was to identify key elements and relevant data that should be detailed in the clinical dataset that accompanies a biological sample. Methods A total of 120 participants were included in this study that were divided into three categories that represent key actors in the development and management of a cancer biobank - clinicians (n=40), scientific researchers (n=40), and oncology patients (n=40). Results The survey indicated that the terms 'biobank' and 'personalized medicine' are unknown only in a proportion of patients, while for the other two groups, these terms are already known. The second questionnaire allowed the arrangement of a recommended clinical dataset to be filled when a biological sample is provided to be included in a cancer biobank. Conclusions The trust of patients and healthcare professionals in building biobanks that adhere to ethical and operational standards in Romania is important, as the development of artificial intelligence and databases allows advanced knowledge and connection of findings from different databases and, therefore, brings the concept of personalized medicine closer to the clinical practice. The information included in this dataset will be integrated and constitutes a comprehensive biobank database. All these aspects are meant to increase the utility of the specimens in cancer research, as clearly annotated samples, along with prospective data, bring valuable knowledge that helps scientific researchers and clinicians make the clinical connection between the molecular alterations and the phenotype of particular patients or a disease.
Collapse
Affiliation(s)
- Liliana Policiuc
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Cecilia Bica
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Cristina Ciocan
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Daniel Corneliu Leucuta
- Department of Medical Informatics and Biostatistics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Andreea Nutu
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Ioana Berindan-Neagoe
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| |
Collapse
|
8
|
Hanin A, Cespedes J, Pulluru Y, Gopaul M, Aronica E, Decampo D, Helbig I, Howe CL, Huttner A, Koh S, Navarro V, Taraschenko O, Vezzani A, Wilson MR, Xian J, Gaspard N, Hirsch LJ. Review and standard operating procedures for collection of biospecimens and analysis of biomarkers in new onset refractory status epilepticus. Epilepsia 2023; 64:1444-1457. [PMID: 37039049 PMCID: PMC10756682 DOI: 10.1111/epi.17600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 03/27/2023] [Accepted: 03/28/2023] [Indexed: 04/12/2023]
Abstract
New onset refractory status epilepticus (NORSE), including its subtype with a preceding febrile illness known as febrile infection-related epilepsy syndrome (FIRES), is one of the most severe forms of status epilepticus. The exact causes of NORSE are currently unknown, and there is so far no disease-specific therapy. Identifying the underlying pathophysiology and discovering specific biomarkers, whether immunologic, infectious, genetic, or other, may help physicians in the management of patients with NORSE. A broad spectrum of biomarkers has been proposed for status epilepticus patients, some of which were evaluated for patients with NORSE. Nonetheless, none has been validated, due to significant variabilities in study cohorts, collected biospecimens, applied analytical methods, and defined outcome endpoints, and to small sample sizes. The NORSE Institute established an open NORSE/FIRES biorepository for health-related data and biological samples allowing the collection of biospecimens worldwide, promoting multicenter research and sharing of data and specimens. Here, we suggest standard operating procedures for biospecimen collection and biobanking in this rare condition. We also propose criteria for the appropriate use of previously collected biospecimens. We predict that the widespread use of standardized procedures will reduce heterogeneity, facilitate the future identification of validated biomarkers for NORSE, and provide a better understanding of the pathophysiology and best clinical management for these patients.
Collapse
Affiliation(s)
- Aurélie Hanin
- Department of Neurology and Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
- Sorbonne Université, Institut du Cerveau ICM, Paris Brain Institute, Inserm, CNRS, Assistance Publique -Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neurosciences 6, Paris, France
- Assistance Publique -Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neurosciences 6, Epilepsy Unit and Department of Clinical Neurophysiology, Paris, France
| | - Jorge Cespedes
- Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
- Universidad Autonoma de Centro America, School of Medicine, San Jose, Costa Rica
| | - Yashwanth Pulluru
- Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
- Nebraska Medical Center, Omaha, Nebraska, USA
| | - Margaret Gopaul
- Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Eleonora Aronica
- Department of (Neuro) Pathology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Danielle Decampo
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Epilepsy NeuroGenetics Initiative, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Ingo Helbig
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Epilepsy NeuroGenetics Initiative, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Charles L. Howe
- Division of Experimental Neurology, Mayo Clinic, Rochester, Minnesota, USA
- Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA
| | - Anita Huttner
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Sookyong Koh
- Department of Pediatrics, Children’s Hospital Medical Center, University of Nebraska, Omaha, Nebraska, USA
| | - Vincent Navarro
- Sorbonne Université, Institut du Cerveau ICM, Paris Brain Institute, Inserm, CNRS, Assistance Publique -Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neurosciences 6, Paris, France
- Assistance Publique -Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neurosciences 6, Epilepsy Unit and Department of Clinical Neurophysiology, Paris, France
| | - Olga Taraschenko
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Annamaria Vezzani
- Department of Acute Brain Injury, Istituto di Recerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Michael R. Wilson
- Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, California, San Francisco, USA
| | - Julie Xian
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Epilepsy NeuroGenetics Initiative, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - Nicolas Gaspard
- Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
- Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium
| | - Lawrence J. Hirsch
- Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
9
|
Al-Shami KM, Ahmed WS, Alzoubi KH. Attitudes Toward Providing Open Access for Use of Biospecimens and Health Records: A Cross-Sectional Study from Jordan. Patient Prefer Adherence 2023; 17:895-903. [PMID: 37013082 PMCID: PMC10066730 DOI: 10.2147/ppa.s402769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Accepted: 03/18/2023] [Indexed: 03/30/2023] Open
Abstract
Purpose Biospecimen repositories and big data generated from clinical research are critically important in advancing patient-centered healthcare. However, ethical considerations arising from reusing clinical samples and health records for subsequent research pose a hurdle for big-data health research. This study aims to assess the public's opinions in Jordan toward providing blanket consent for using biospecimens and health records in research. Participants and Methods A cross-sectional study utilizing a self-reported questionnaire was carried out in different cities in Jordan, targeting adult participants. Outcome variables included awareness of clinical research, participation in clinical research, and opinions toward providing open access to clinical samples and records for research purposes. Descriptive analysis was utilized for reporting the outcome as frequency (percentages) out of the total responses. Univariate and multivariate logistic regression were used to investigate the association between independent variables and the outcome of interest. Results A total of 1033 eligible participants completed the questionnaire. Although the majority (90%) were aware of clinical research, only 24% have ever participated in this type of research. About half (51%) agreed on providing blanket consent for the use of clinical samples, while a lower percentage (43%) agreed on providing open access to their health records. Privacy concerns and lack of trust in the researcher were cited as major barriers to providing blanket consent. Participation in clinical research and having health insurance were predictors for providing open access to clinical samples and records. Conclusion The lack of public trust in Jordan toward data privacy is evident from this study. Therefore, a governance framework is needed to raise and maintain the public's trust in big-data research that warrants the future reuse of clinical samples and records. As such, the current study provides valuable insights that will inform the design of effective consent protocols required in data-intensive health research.
Collapse
Affiliation(s)
- Kamal M Al-Shami
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan
- Faculty of Biosciences, University of Heidelberg, Heidelberg, 69120, Germany
| | - Wesam S Ahmed
- College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar
| | - Karem H Alzoubi
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan
| |
Collapse
|
10
|
Neuber AC, Komoto TT, da Silva ECA, Duval VDS, Scapulatempo-Neto C, Marques MMC. Quality Assessment of Cryopreserved Human Biological Samples from the Biobank of Barretos Cancer Hospital. Biopreserv Biobank 2023; 21:74-80. [PMID: 35613409 DOI: 10.1089/bio.2021.0131] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: Biobanks process, store, and supply biological materials for research. Preanalytical factors, especially storage time and temperature, must be controlled and standardized at all stages when handling biospecimen samples, especially because the literature reports highly contradictory optimal parameters. As large-sample studies are required to better understand the influence of time and temperature on cryopreserved samples' quality for genomic research, this study evaluated the integrity and quality of cryopreserved samples stored for up to 9 years at the biobank of Barretos Cancer Hospital, one of the largest biobanks in Latin America. Methods: We randomly selected 447 samples with tumor tissue paired with buffy coat or peripheral blood mononuclear cells (PBMCs) that were stored from 2008 to 2016. The genetic material quality was evaluated based on RNA integrity (RIN) and DNA integrity (DIN) ≥7, which indicated undegraded samples, and compared with storage time, which means that for DNA storage time, samples <8.1 and ≥8.1 years and for RNA <4.5 and ≥4.5 were used. Results: A total of 190 tumor tissues were eligible for DNA and RNA extraction. Those stored for 8 years had lower DIN (68%) than those stored for a shorter period (92%). A similar pattern, based on storage time (<8.1 and ≥8.1 years), was observed in the buffy coat (74% and 95%, respectively) and PBMCs (54% and 96%, respectively). For RNA extracted from tumor tissues, we observed lower RIN in samples stored for 4.5 years (17%) than in samples stored for a shorter period (45%). Buffy coat and PBMC samples stored at -30°C exhibited greater degradation (26%) than those stored at -80°C (1%). The DIN (p = 0.15) and RNA (p = 0.18) were unrelated to topography type. Conclusion: The temperature, particularly cryopreservation methodology, and storage time were the main factors that affected nucleic acid integrity, especially RNA, during cryopreservation of biospecimens.
Collapse
Affiliation(s)
| | | | | | - Vinicius da Silva Duval
- Barretos Cancer Hospital Biobank, Barretos, Brazil.,Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil
| | | | - Márcia M C Marques
- Barretos Cancer Hospital Biobank, Barretos, Brazil.,Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.,Barretos School of Health Sciences, Barretos, Brazil
| |
Collapse
|
11
|
Cross N, Clark J, Perez-Iratxeta C, Nagasawa A. Data profile: The Statistics Canada Biobank. Health Rep 2022; 33:27-34. [PMID: 36441616 DOI: 10.25318/82-003-x202201100003-eng] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Introduction The Statistics Canada Biobank (Biobank) is a valuable source of nationally representative health information. It contains biospecimens collected from the Canadian Health Measures Survey (CHMS) and the Canadian COVID-19 Antibody and Health Survey (CCAHS). Both surveys are voluntary and aim to collect a variety of important health information from Canadians to create nationally representative estimates. This information is collected through questionnaires, physical measures, and self-administered sample collection. Biospecimens collected as part of the CHMS and CCAHS from consenting participants include whole blood, plasma, serum, urine, DNA samples, and dried blood spots. These samples are stored as part of the Biobank for future health research. Canadian researchers can apply to the Biobank program to use this nationally representative source of biospecimens. Results obtained from their research can also be combined with a wide variety of health and lifestyle information collected as part of the CHMS and CCAHS, making the Biobank a rich source of health-related information that can fill data gaps on the health concerns that are important to Canadians. This data resource profile provides an overview of the Biobank to inform researchers and data users about the program and how it can be used as a resource for the advancement of health-related research.
Collapse
Affiliation(s)
- Natalie Cross
- Centre for Direct Health Measures, Statistics Canada
| | - Janine Clark
- Centre for Direct Health Measures, Statistics Canada
| | | | | |
Collapse
|
12
|
Buhmeida A, Assidi M, Alyazidi O, Olwi DI, Althuwaylimi A, Yahya FM, Arfaoui L, Merdad L, Abuzenadah AM. Assessment of Biobanking Knowledge and Attitudes towards Biospecimen Donation among Healthcare Providers in Saudi Arabia. Int J Environ Res Public Health 2022; 19:11872. [PMID: 36231176 PMCID: PMC9565163 DOI: 10.3390/ijerph191911872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 09/06/2022] [Accepted: 09/12/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Biobanking is a critical cornerstone of the global shift towards precision medicine (PM). This transformation requires smooth and informed interaction between a range of stakeholders involved in the healthcare system. In Saudi Arabia, there is still insufficient awareness of the importance of biobanking and its potential benefits for patients, the healthcare system, and society as a whole. The purpose of this study was to determine the biobanking knowledge of Saudi healthcare providers and the potential factors that might influence their self-reported attitudes toward biospecimen donation and biobanking. METHODS A cross-sectional study was conducted targeting 636 healthcare providers in Makkah province using a structured, self-administered questionnaire. RESULTS The study had a response rate of 61%. The mean knowledge level about biobanks was 3.5 (±1.8) out of 7. About one-third of the participants were aware of the Human Genome Project (HGP) (35%) or the term "biobank" (34%). The mean rating of their attitude was 37.3 (±4.3) out of 55. Most participants (74%) had a positive attitude toward medical research. Job position, general health, previous blood tests, knowledge of biobanking, and attitudes toward biomedical research were significantly related and predictors of willingness to donate biospecimens (p < 0.05). However, concerns about biospecimen misuse and confidentiality were the main reasons for not donating biospecimens. CONCLUSIONS This study has shown that healthcare providers mostly lack basic knowledge about HGP and biobanks and their roles and activities, and therefore are generally disinclined to actively participate in biospecimens' collection and management. It is recommended that medical trainees receive more education and awareness about biobanks and the latest personalized healthcare approaches to improve translational research outcomes and achieve precision medicine.
Collapse
Affiliation(s)
- Abdelbaset Buhmeida
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| | - Mourad Assidi
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 22254, Saudi Arabia
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| | - Omar Alyazidi
- Public Health Administration, Directorate of Health Affairs of Jeddah Region, Ministry of Health, Jeddah 23222, Saudi Arabia
| | - Duaa Ibrahim Olwi
- King Abdullah International Medical Research Center, Jeddah 22384, Saudi Arabia
- King Saud bin Abdulaziz University for Health Sciences, Jeddah 22384, Saudi Arabia
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 1TN, UK
| | - Ahmed Althuwaylimi
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield S10 2TN, UK
| | - Fatimah M. Yahya
- Biochemistry Department, Faculty of Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| | - Leila Arfaoui
- Clinical Nutrition Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| | - Leena Merdad
- Faculty of Dentistry, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| | - Adel Mohammad Abuzenadah
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 22254, Saudi Arabia
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| |
Collapse
|
13
|
López-Guerrero JA, Mendiola M, Pérez-Fidalgo JA, Romero I, Torres A, Recalde D, Molina E, Gómez-Raposo C, Levin AM, Herrero A, Alarcón J, Esteban C, Marquina G, Rubio MJ, Guerra E, Sánchez-Lorenzo L, Gálvez-Montosa F, de Juan A, Churruca C, Gallego A, González-Martín A. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network. Cancers (Basel) 2022; 14:cancers14081965. [PMID: 35454870 PMCID: PMC9031046 DOI: 10.3390/cancers14081965] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 04/07/2022] [Accepted: 04/08/2022] [Indexed: 02/04/2023] Open
Abstract
Patient registries linked to biorepositories constitute a valuable asset for clinical and translational research in oncology. The Spanish Group of Ovarian Cancer Research (GEICO), in collaboration with the Spanish Biobank Network (RNBB), has developed a multicentre, multistakeholder, prospective virtual clinical registry (VCR) associated with biobanks for the collection of real-world data and biological samples of gynaecological cancer patients. This collaborative project aims to promote research by providing broad access to high-quality clinical data and biospecimens for future research according to the needs of investigators and to increase diagnostic and therapeutic opportunities for gynaecological cancer patients in Spain. The VCR will include the participation of more than 60 Spanish hospitals entering relevant clinical information in harmonised electronic case report forms (eCRFs) in four different cohorts: ovarian, endometrial, cervical, and rare gynaecological cancers (gestational trophoblastic disease). Initial data for the cases included till December 2021 are presented. The model described herein establishes a real-world win-win collaboration between multicentre structures, promoted and supported by GEICO, that will contribute to the success of translational research in gynaecological cancer.
Collapse
Affiliation(s)
- José Antonio López-Guerrero
- Laboratorio de Biología Molecular y Biobanco, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain
- Unidad Mixta de Investigación en Cáncer IVO-CIPF, Centro de Investigación Príncipe Felipe (CIPF), 46012 Valencia, Spain
- Departamento de Patología, Facultad de Medicina, Universidad Católica de Valencia ‘San Vicente Martir’, 46001 Valencia, Spain
- Correspondence: ; Tel.: +34-961114337
| | - Marta Mendiola
- Laboratorio de Patología Molecular y Dianas Terapéuticas, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), 28029 Madrid, Spain;
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - José Alejandro Pérez-Fidalgo
- Departamento de Oncología Médica, Hospital Clinico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, CIBERONC, 46010 Valencia, Spain;
| | - Ignacio Romero
- Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain;
| | - Ana Torres
- Biobanco del Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain;
| | - Delia Recalde
- Biobanco del Sistema de Salud de Aragón, 50009 Zaragoza, Spain;
| | - Elena Molina
- Biobanco del Hospital Clínico San Carlos, 28040 Madrid, Spain;
| | - César Gómez-Raposo
- Department of Medical Oncology, Hospital Universitario Infanta Sofía, 28703 Madrid, Spain;
| | - Ana M. Levin
- Grupo Español de Investigación en Cáncer de Ovario, 28003 Madrid, Spain;
| | - Ana Herrero
- Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain;
| | - Jesús Alarcón
- Department of Medical Oncology, Hospital Universitario Son Espases, 07120 Palma, Spain;
| | - Carmen Esteban
- Department of Medical Oncology, Hospital Virgen de la Salud, 45004 Toledo, Spain;
| | - Gloria Marquina
- Department of Medical Oncology, Hospital Clínico San Carlos, 28040 Madrid, Spain;
| | - María Jesús Rubio
- Department of Medical Oncology, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain;
| | - Eva Guerra
- Department of Medical Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain;
| | - Luisa Sánchez-Lorenzo
- Department of Medical Oncology, Clínica Universidad de Navarra, 28027 Madrid, Spain; (L.S.-L.); (A.G.-M.)
| | | | - Ana de Juan
- Department of Medical Oncology, Hospital Univeristario Marqués de Valdecilla, 39008 Santander, Spain;
| | - Cristina Churruca
- Department of Medical Oncology, Hospital Universitario Donostia, 20014 Donostia, Spain;
| | - Alejandro Gallego
- Department of Medical Oncology, Hospital Universitario La Paz, 28029 Madrid, Spain;
| | - Antonio González-Martín
- Department of Medical Oncology, Clínica Universidad de Navarra, 28027 Madrid, Spain; (L.S.-L.); (A.G.-M.)
- Programa de Tumores Sólidos, Centro de Investigación de Medicina Aplicada (CIMA), 31008 Pamplona, Spain
| |
Collapse
|
14
|
Klitzman R. Henrietta Lacks' family's lawsuits: ethical questions and solutions. Trends Biotechnol 2022; 40:769-772. [PMID: 35341603 DOI: 10.1016/j.tibtech.2022.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 02/23/2022] [Accepted: 02/24/2022] [Indexed: 11/28/2022]
Abstract
The family of Henrietta Lacks has begun suing companies for using her cells, raising ethical and legal questions affecting research. Benefits and burdens should be shared among patients and researchers, but do not necessarily warrant cash transfers through lawsuits. This discussion has crucial implications for profits from donations of biospecimens.
Collapse
Affiliation(s)
- Robert Klitzman
- Masters of Bioethics Program, Columbia University, New York, NY, USA.
| |
Collapse
|
15
|
Campbell G, Dixon MD, Lohani M, Cook J, Hianik R, Thomson MC, Abernethy E, Lewis C, Switchenko J, Harvey RD, Pentz RD. Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding? Ethics Hum Res 2022; 44:18-25. [PMID: 35218599 PMCID: PMC9069479 DOI: 10.1002/eahr.500120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
In phase I trials, some biospecimens are used both for research and patient care and some for research only. Some research participants have therapeutic misconception, assuming all biospecimens are for patient care. This study's aim was to test if a simple information chart would improve understanding of nontherapeutic research procedures. A two-arm study was conducted. Participants in the control group (C) were asked whether biospecimens were for their care, for research only, or for both. The experimental group (E) was asked the same questions but provided with a study-specific information chart labeling the purpose of each biospecimen. One hundred one patients were interviewed. In both arms, understanding that pretreatment blood draws were for patient care and research was moderate (49% for C and 62% for E). Understanding that posttreatment blood draws were for research only was significantly higher in the experimental arm (16% for C and 44% for E; p = 0.002). Providing a simple information chart may help alleviate this aspect of therapeutic misconception.
Collapse
Affiliation(s)
- Gavin Campbell
- Research assistant at the Winship Cancer Institute of Emory University
| | - Margie D Dixon
- Supervisor and project coordinator at the Winship Cancer Institute of Emory University
| | - Minisha Lohani
- Internal medicine resident at the Stony Brook University School of Medicine
| | - John Cook
- Medical student at the Uniformed Services University of the Health Sciences School of Medicine
| | - Rachel Hianik
- Medical student at the University of North Carolina School of Medicine
| | | | - Eli Abernethy
- Medical student at Duke University School of Medicine
| | - Colleen Lewis
- Nurse practitioner at the Winship Cancer Institute of Emory University
| | | | - R Donald Harvey
- Phase I director at the Winship Cancer Institute of Emory University
| | - Rebecca D Pentz
- Professor of research ethics at the Winship Cancer Institute of Emory University
| |
Collapse
|
16
|
Shin HM, Oh J, Kim K, Busgang SA, Barr DB, Panuwet P, Schmidt RJ, Picciotto IH, Bennett DH. Variability of Urinary Concentrations of Phenols, Parabens, and Triclocarban during Pregnancy in First Morning Voids and Pooled Samples. Environ Sci Technol 2021; 55:16001-16010. [PMID: 34817155 PMCID: PMC8858442 DOI: 10.1021/acs.est.1c04140] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Urinary concentrations of phenols, parabens, and triclocarban have been extensively used as biomarkers of exposure. However, because these compounds are quickly metabolized and excreted in urine, characterizing participants' long-term average exposure from a few spot samples is challenging. To examine the variability of urinary concentrations of these compounds during pregnancy, we quantified four phenols, four parabens, and triclocarban in 357 first morning voids (FMVs) and 203 pooled samples collected during the second and third trimesters of 173 pregnancies. We computed intraclass correlation coefficients (ICCs) by the sample type (FMV and pool) across two trimesters and by the number of composite samples in pools, ranging from 2 to 4, within the same trimester. Among the three compounds detected in more than 50% of the samples, the ICCs across two trimesters were higher in pools (0.29-0.68) than in FMVs (0.17-0.52) and the highest ICC within the same trimester was observed when pooling either two or three composites. Methyl paraben and propyl paraben primarily exposed via cosmetic use had approximately 2-3 times higher ICCs than bisphenol A primarily exposed via diet. Our findings support that within-subject pooling of biospecimens can increase the reproducibility of pregnant women's exposure to these compounds and thus could potentially minimize exposure misclassification.
Collapse
Affiliation(s)
- Hyeong-Moo Shin
- Department of Earth and Environmental Sciences, University of Texas, Arlington, Texas, USA
- Corresponding author: Hyeong-Moo Shin, Ph.D., Department of Earth and Environmental Sciences, University of Texas, Arlington, 500 Yates Street, Box 19049, Arlington, TX, 76019, ; Voice: 949-648-1614
| | - Jiwon Oh
- Department of Earth and Environmental Sciences, University of Texas, Arlington, Texas, USA
| | - Kyunghoon Kim
- Department of Environmental Engineering, Seoul National University of Science and Technology, Seoul, Korea
| | - Stefanie A. Busgang
- Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Dana Boyd Barr
- Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Parinya Panuwet
- Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Rebecca J. Schmidt
- Department of Public Health Sciences, University of California, Davis (UC Davis), California, USA
- UC Davis MIND (Medical Investigations of Neurodevelopment Disorders) Institute, UC Davis, Davis, California, USA
| | - Irva Hertz Picciotto
- Department of Public Health Sciences, University of California, Davis (UC Davis), California, USA
- UC Davis MIND (Medical Investigations of Neurodevelopment Disorders) Institute, UC Davis, Davis, California, USA
| | - Deborah H. Bennett
- Department of Public Health Sciences, University of California, Davis (UC Davis), California, USA
| |
Collapse
|
17
|
Gao F, Tao L, Ma X, Lewandowski D, Shu Z. A Study of Policies and Guidelines for Collecting, Processing, and Storing Coronavirus Disease 2019 Patient Biospecimens for Biobanking and Research. Biopreserv Biobank 2020; 18:511-516. [PMID: 33290126 DOI: 10.1089/bio.2020.0099] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Biobanking has been playing a crucial role in the development of new vaccines, drugs, biotechnology, and therapeutics for the prevention and treatment of a wide range of human diseases. This puts biobanks at the forefront of responding to the ongoing worldwide outbreak of the severe pandemic, coronavirus disease 2019 (COVID-19). The leading public health institutions around the world have developed and established interim policies and guidelines for researchers and biobank staff to handle the infectious biospecimens safely and adequately from COVID-19 patients. A study of these important and complementary policies and guidelines is conducted in this study. It should be emphasized that the COVID-19 biospecimens must be collected, processed, and preserved by trained personnel equipped with right personal protective equipment to prevent the transmission of the coronavirus and ensure the specimen quality for testing and research. Six of the leading global public health organizations or institutions included in this study are the World Health Organization, the Pan American Health Organization, the U.S. Centers for Disease Control and Prevention, the Public Health England, the U.S. Food and Drug Administration, and the Office of Research at the University of California, San Francisco. In conclusion, following the recommended guidance and policies with extreme precautions is essential to ensure the quality of the collected COVID-19 biospecimens and accuracy of the conducted research or treatment, and prevent any possible transmission. Efforts from cryobiologist and biobanking engineers to optimize the protocol of COVID-19 biospecimen cryopreservation and develop the user-friendly and cost-effective devices are urgently required to meet the urgent and increased needs in the specimen biobanking and transportation.
Collapse
Affiliation(s)
- Frank Gao
- School of Public Affairs, University of Science and Technology of China, Hefei, Anhui, China
| | - Liang Tao
- Department of Mechanical Engineering, University of California-Berkeley, Berkeley, California, USA
| | - Xiao Ma
- Department of Mechanical Engineering, University of Washington, Seattle, Washington, USA
| | - David Lewandowski
- Global Business Development, Brooks Life Sciences, Chelmsford, Massachusetts, USA
| | - Zhiquan Shu
- Department of Mechanical Engineering, University of Washington, Seattle, Washington, USA.,School of Engineering and Technology, University of Washington Tacoma, Tacoma, Washington, USA
| |
Collapse
|
18
|
Maki KC, Miller JW, McCabe GP, Raman G, Kris-Etherton PM. Perspective: Laboratory Considerations and Clinical Data Management for Human Nutrition Randomized Controlled Trials: Guidance for Ensuring Quality and Integrity. Adv Nutr 2020; 12:46-58. [PMID: 33200184 PMCID: PMC7849975 DOI: 10.1093/advances/nmaa088] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 06/25/2020] [Accepted: 06/30/2020] [Indexed: 11/14/2022] Open
Abstract
In human nutrition randomized controlled trials (RCTs), planning, and careful execution of clinical data collection and management are vital for producing valid and reliable results. In this article, we provide an overview of best practices for biospecimen collection and analyses, and for the fundamentals of clinical data management, including preparation and study startup; data collection, entry, cleaning, and authentication; and database lock. The reader is also referred to additional resources for information to assist in the planning and conduct of human RCTs. The tools and strategies described are expected to improve the quality of data produced in human nutrition research that can, therefore, be used to support food and nutrition policies.
Collapse
Affiliation(s)
| | - Joshua W Miller
- Department of Nutritional Sciences, Rutgers University, New Brunswick, NJ, USA
| | - George P McCabe
- Department of Statistics, Purdue University, West Lafayette, IN, USA
| | - Gowri Raman
- Institute for Clinical Research and Health Policy Studies, Center for Clinical Evidence Synthesis (CCES), Tufts Medical Center, Boston, MA, USA
| | - Penny M Kris-Etherton
- Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA
| |
Collapse
|
19
|
Page SA, Collisson BA, Godley J, Nguyen D, Metz L, Muruve D. How Semantics Connotations May Influence Concerns About Donation of Biospecimens. Biopreserv Biobank 2020; 19:156-162. [PMID: 33179960 PMCID: PMC8217592 DOI: 10.1089/bio.2020.0072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Introduction: Human biological specimen (biospecimen) donation is routinely requested for clinical care and research purposes. Successfully engaging patients and research participants in biospecimen donation depends on what they understand these initiatives entail, including their perceptions of risk. Human biospecimens are stored in facilities routinely referenced as biobanks or biorepositories, both of which labels are known to embody a variety of connotations. The words chosen to describe biospecimen facilities may influence decisions about donation. Objective: To explore differences in likelihood of donation as a function of the words chosen to represent human biospecimen storage facilities and the commensurate concerns each label evokes. Materials and Methods: Two-group experimental design. Participants completed a survey about a fictitious undertaking requesting that they consider biospecimen donation. The term used to describe the facility housing the biospecimens differed; one half of the surveys referenced a biobank, and one half referenced a biorepository. Results: Two thousand five hundred ninety-six surveys were distributed; 586 completed surveys were received (response rate: 22.6%). Sixty-three percent of respondents, regardless of whether the label referenced a biobank or biorespository, reported being extremely likely to donate. There were no significant differences between the 2 groups on the 11 concerns sampled. Factor analyses revealed that concerns could be classified in two groups: use-related concerns and person-related concerns. The label biobank evoked significantly lower perception of importance of the person-related concerns sampled (e.g., personal or other benefit, discomfort or inconvenience). Conclusions: Our results suggest that researchers may consider using the word biobank to describe the facility housing the biospecimen, as this term appears less subject to concern biases. These outcomes confirm that misunderstandings or misattributions of words used to refer to biospecimen facilities could deter participation in clinical care or research. Participation may be enhanced through ensuring clear understanding of what biospecimen donation entails and by directly addressing common semantic misunderstandings and associations.
Collapse
Affiliation(s)
- Stacey A Page
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Beverly Anne Collisson
- Department of Pediatrics, Cumming School of Medicine, The Owerko Centre at the Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Canada
| | - Jenny Godley
- Department of Sociology, Faculty of Arts, University of Calgary, Calgary, Canada
| | - Danny Nguyen
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Luanne Metz
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Daniel Muruve
- Division of Nephrology, Department of Medicine, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada
| |
Collapse
|
20
|
Abstract
The Covid-19 crisis has underscored the importance of the collection and analysis of clinical and research data and specimens for ongoing work. The federal government recently completed a related revision of the human subjects research regulations, founded in the traditional principles of research ethics, but in this commentary, we argue that the analysis underpinning this revision overemphasized the importance of informed consent, given the low risks of secondary research. Governing the interests of a community is different from governing the interests of individuals, and here we suggest that, moving forward, the analyses of the risks of secondary research protocols be assessed from the perspective of the former.
Collapse
|
21
|
Rothwell E, Johnson E, Wong B, Goldenberg A, Tarini BA, Riches N, Stark LA, Pries C, Langbo C, Langen E, Botkin J. Comparison of Video, App, and Standard Consent Processes on Decision-Making for Biospecimen Research: A Randomized Controlled Trial. J Empir Res Hum Res Ethics 2020; 15:252-260. [PMID: 32242760 DOI: 10.1177/1556264620913455] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Obtaining informed consent for bloodspot research from newborn screening is particularly challenging due to the hectic environment of the postnatal period and the relatively abstract nature of future, unspecified research on the biospecimens. A randomized controlled trial was conducted in three Michigan hospitals to compare two different consent processes (video and interactive tablet "app") with standard brochure-based consent in the Michigan BioTrust for Health. Results indicated higher knowledge scores for the video and app groups as well as significantly higher scores on satisfaction, amount of information, and clarity with the information provided. More research is needed to find the right amount of information for informed decision-making, and additional feasibility studies are needed to assess implementation strategies.
Collapse
Affiliation(s)
| | | | - Bob Wong
- The University of Utah, Salt Lake City, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Doludin YV, Borisova AL, Pokrovskaya MS, Stefanyuk OV, Sivakova OV, Botsoeva SA, Meshkov AN, Metelskaya VA, Drapkina OM. [Current best practices and biobanking recomedations.]. Klin Lab Diagn 2020; 64:769-776. [PMID: 32040903 DOI: 10.18821/0000-0000-0000-00-0-0-00] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Accepted: 10/30/2019] [Indexed: 11/17/2022]
Abstract
The biobank is a structure established with the goal of long-term responsible storage of biological samples and the associated data for their further use in scientific and clinical research. The objectives of biobanking are the creation of unified recommendations on: the planning of premises and the selection of equipment for storage; development of management methods and staff training; standardization of methods for the collection, shipping, processing and storage of biomaterial of various origins, as well as methods for quality control and validation of the applied methods; creation and use of databases of information accompanying biospecimens. The lack of common standards for conducting the preanalytical phase has been the cause of low accuracy and poor reproducibility of research results. To date, a large number of guidelines and best practices have been published that provide an answer to a wide range of problems in organizing the biobanking process. The article provides an overview of the most famous biobanking guidelines that can be used to solve various research problems. Biobanking in Russia is actively developing. Since 1996 there is a work on the legislative regulation of biobanking activities, as a result of which a number of regulatory documents have been issued. An important stage in the development of biobanking in Russia was the establishment of the "National Association of Biobanks and Biobanking Specialists" (NASBio) in 2018, which included representatives of medical and research institutions, commercial firms, and qualified specialists in the field of biobanking. One of the key tasks of NASBio is the adaptation and implementation of the best biobanking practices in Russian research institutes and centers. The use of modern guidelines and best practices on biobanking will lead to an increase in the quality of research and publications.
Collapse
Affiliation(s)
- Y V Doludin
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - A L Borisova
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - M S Pokrovskaya
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - O V Stefanyuk
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - O V Sivakova
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - S A Botsoeva
- FSI 52 Consulting and Diagnostic Center of the Ministry of Defense of the Russian Federation, 125167, Moscow, Russia
| | - A N Meshkov
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - V A Metelskaya
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| | - O M Drapkina
- FSI National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 101990, Moscow, Russia
| |
Collapse
|
23
|
Adishesh M, Hapangama DK. Enriching Personalized Endometrial Cancer Research with the Harmonization of Biobanking Standards. Cancers (Basel) 2019; 11:E1734. [PMID: 31694311 DOI: 10.3390/cancers11111734] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Revised: 10/31/2019] [Accepted: 11/02/2019] [Indexed: 12/14/2022] Open
Abstract
Endometrial cancer is the commonest gynecological cancer, with an incidence predicted to escalate by a further 50–100% before 2025, due to the rapid rise in risk factors such as obesity and increased life expectancy. Endometrial cancer associated mortality is also rising, depicting the need for translatable research to improve our understanding of the disease. Rapid translation of scientific discoveries will facilitate the development of new diagnostic, prognostic and therapeutic strategies. Biobanks play a vital role in providing biospecimens with accompanying clinical data for personalized translational research. Wide variation in collection, and pre-analytic variations in processing and storage of bio-specimens result in divergent and irreproducible data from multiple studies that are unsuitable for collation to formulate robust conclusions. Harmonization of biobanking standards is thus vital, in facilitating international multi-center collaborative studies with valuable outcomes to improve personalized treatments. This review will detail the pitfalls in the biobanking of biosamples from women with cancer in general, and describe the recent international harmonization project that developed standardized research tools to overcome these challenges and to enhance endometrial cancer research, which will facilitate future development of personalized novel diagnostic strategies and treatments.
Collapse
|
24
|
Abstract
It has been over 5 years since the last special issue of Twin Research and Human Genetics on 'Twin Registries Worldwide: An Important Resource for Scientific Research' was published. Much progress has been made in the broad field of twin research since that time, and the current special issue is a follow-up to update the scientific community about twin registries around the globe. The present article builds upon our 2013 Registry description by summarizing current information on the Washington State Twin Registry (WSTR), including history and construction methods, member characteristics, available data, and major research goals. We also provide a section with brief summaries of recently completed studies and discuss the future research directions of the WSTR. The Registry has grown in terms of size and scope since 2013; highlights include recruitment of youth pairs under 18 years of age, extensive geocoding work to develop environmental exposures that can be linked to survey and administrative health data such as death records, and expansion of a biobank with specimens collected for genotyping, DNA methylation, and microbiome based-studies.
Collapse
|
25
|
Abstract
Bioresources are critical resources that support biomedical research because of their ability to appropriately collect, process, store, and distribute a wide range of high-quality biospecimens that meet the needs of specific investigators. Of note, some biorepositories are concerned by their growing inventories and their low rates of tissue utilization. This review discusses the technical characteristics of biospecimens that can cause morphological and molecular variability and/or limit the usefulness of biospecimens in research. This article also describes current challenges related to biospecimen characteristics that may affect biospecimen utilization. These include inadequate awareness of investigators about the availability of biospecimens with specific morphologic and molecular features, donor variability, preanalytical variables, technical problems inherent with an investigator's request for biospecimens, limited tissue availability from a biorepository based on requested sizes and/or numbers of available biospecimens, effects of times of warm and cold ischemia, damage of tissues during surgery, and molecular changes during storage. To ensure maximal biospecimen utilization of all types of biospecimens requires continual education of investigators from diverse fields, particularly on factors that cause variability in the morphological and molecular characteristics of tissues. The investigators' requests for biospecimens and associated data should be reviewed carefully, including by a bioresource-associated pathologist. Queries arising from the request/application form should be resolved by bioresource personnel directly with the investigator.
Collapse
Affiliation(s)
- Dennis Otali
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Sameer Al Diffalha
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - William E. Grizzle
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
- The Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
26
|
Abstract
Many classic biobanks collect more human tissues than they distribute, leading to increased inventories, unnecessary storage, increased expenses, and reduced chargeback income. This situation is a result of biobanks operating without well-defined goals, having incorrect views of the potential number of investigators who will utilize specimens, and collection of biospecimens without adequately considering the need for specific tissues by investigators. These deficiencies frequently lead to unrealistic plans for biospecimen utilization and biobanks that are larger than necessary. For example, tissue collections usually are not periodically compared with biospecimen distribution and modified accordingly. An ethical issue has arisen as to the acceptability of consenting patients for the use of their tissues in research without a realistic planned approach to distribution of the biospecimens and their ultimate utilization in supporting biomedical research. These issues and how to minimize them are discussed in this commentary focused on how classic biobanks can improve utilization of their biospecimens.
Collapse
Affiliation(s)
- William E. Grizzle
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
- Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Katherine C. Sexton
- Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
27
|
Fisher WE, Cruz-Monserrate Z, McElhany AL, Lesinski GB, Hart PA, Ghos R, Van Bure G, Fishman DS, Rinaudo JAS, Serrano J, Srivastava S, Mace T, Topazian M, Feng Z, Yadav D, Pandol SJ, Hughes SJ, Liu RY, Lu E, Orr R, Whitcomb DC, Abouhamze AS, Steen H, Sellers ZM, Troendle DM, Uc A, Lowe ME, Conwell DL. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 2019; 47:1213-1221. [PMID: 30325860 PMCID: PMC6197069 DOI: 10.1097/mpa.0000000000001171] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
High-quality and well-annotated biorepositories are needed to better understand the pathophysiology and biologic mechanisms of chronic pancreatitis (CP) and its consequences. We report a methodology for the development of a robust standard operating procedure (SOP) for a biorepository based on the experience of the clinical centers within the consortium to study Chronic Pancreatitis, Diabetes and Pancreas Cancer Clinical Centers (CPDPC), supported by the National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases as a unique multidisciplinary model to study CP, diabetes, and pancreatic cancer in both children and adults. Standard operating procedures from the CPDPC centers were evaluated and consolidated. The literature was reviewed for standard biorepository operating procedures that facilitated downstream molecular analysis. The existing literature on biobanking practices was harmonized with the SOPs from the clinical centers to produce a biorepository for pancreatic research. This article reports the methods and basic principles behind the creation of SOPs to develop a biorepository for the CPDPC. These will serve as a guide for investigators developing biorepositories in pancreas research. Rigorous and meticulous adherence to standardized biospecimen collection will facilitate investigations to better understand the pathophysiology and biologic mechanisms of CP, diabetes, and pancreatic cancer.
Collapse
Affiliation(s)
- William E. Fisher
- The Elkins Pancreas Center, Michael E. DeBakey Department of Surgery, and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
| | - Zobeida Cruz-Monserrate
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
| | - Amy L. McElhany
- The Elkins Pancreas Center, Michael E. DeBakey Department of Surgery, and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
| | - Gregory B. Lesinski
- Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
| | - Phil A. Hart
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
| | - Ria Ghos
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - George Van Bure
- The Elkins Pancreas Center, Michael E. DeBakey Department of Surgery, and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
| | | | - Jo Ann S. Rinaudo
- Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute (NCI), Rockville, MD
| | - Jose Serrano
- Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD
| | - Sudhir Srivastava
- Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute (NCI), Rockville, MD
| | - Thomas Mace
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
| | - Mark Topazian
- Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
| | - Ziding Feng
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Dhiraj Yadav
- Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
| | - Stephen J. Pandol
- Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA
| | - Steven J. Hughes
- Department of Surgery, University of Florida College of Medicine, Gainesville, FL
| | - Robert Y. Liu
- Clinical Research Support Center, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Emily Lu
- Clinical Research Support Center, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Robert Orr
- Indiana Clinical and Translational Sciences Institute, Specimen Storage Facility, Indianapolis, IN
| | - David C. Whitcomb
- Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
| | - Amer S. Abouhamze
- Clinical and Translational Sciences, University of Florida, Gainesville, FL
| | - Hanno Steen
- Departments of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, MA
| | - Zachary M. Sellers
- Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children’s Hospital and Stanford University School of Medicine, Stanford, CA
| | - David M. Troendle
- Department of Pediatrics, University of Texas Southwestern Medical School, Dallas, TX
| | - Aliye Uc
- Stead Family Department of Pediatrics, University of Iowa, Stead Family Children’s Hospital, Iowa City, IA
| | - Mark E. Lowe
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
| | - Darwin L. Conwell
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
| | | |
Collapse
|
28
|
Rosenstein BS, Rao A, Moran JM, Spratt DE, Mendonca MS, Al‐Lazikani B, Mayo CS, Speers C. Genomics, bio specimens, and other biological data: Current status and future directions. Med Phys 2018; 45:e829-e833. [PMID: 30226926 PMCID: PMC6214357 DOI: 10.1002/mp.12912] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 03/25/2018] [Accepted: 03/26/2018] [Indexed: 11/05/2022] Open
Affiliation(s)
- Barry S. Rosenstein
- Department of Radiation OncologyIcahn School of Medicine at Mount SinaiNew YorkNY10029USA
- Department of Genetics and Genomic SciencesIcahn School of Medicine at Mount SinaiNew YorkNY10029USA
| | - Arvind Rao
- Department of Radiation OncologyUniversity of Michigan Health SystemAnn ArborMI48109USA
| | - Jean M. Moran
- Department of Radiation OncologyUniversity of Michigan Health SystemAnn ArborMI48109USA
| | - Daniel E. Spratt
- Department of Radiation OncologyUniversity of Michigan Health SystemAnn ArborMI48109USA
| | - Marc S. Mendonca
- Department of Radiation OncologyRadiation and Cancer Biology LaboratoriesIndiana University School of MedicineIndianapolisIN46202USA
- Department of Medical & Molecular GeneticsIndiana University School of MedicineIndianapolisIN46202USA
| | - Bissan Al‐Lazikani
- Cancer Research UK Cancer Therapeutics UnitDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonSW7 3RPUK
| | - Charles S. Mayo
- Department of Radiation OncologyUniversity of Michigan Health SystemAnn ArborMI48109USA
| | - Corey Speers
- Department of Radiation OncologyUniversity of Michigan Health SystemAnn ArborMI48109USA
| |
Collapse
|
29
|
Rothwell E, Botkin JR, Cheek-O'Donnell S, Wong B, Case GA, Johnson E, Matheson T, Wilson A, Robinson NR, Rawlings J, Horejsi B, Lopez AM, Byington CL. An empirical assessment of the short-term impacts of a reading of Deborah Zoe Laufer's drama Informed Consent on attitudes and intentions to participate in genetic research. AJOB Empir Bioeth 2018; 9:69-76. [PMID: 29513089 PMCID: PMC6092928 DOI: 10.1080/23294515.2018.1449771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
OBJECTIVE This study assessed the short-term impact of the play "Informed Consent" by Deborah Zoe Laufer (a fictionalized look at the controversy over specimens collected from the Havasupai Tribe for diabetes research in 1989) on perceptions of trust, willingness to donate biospecimens, and attitudes toward harm and privacy among the medical and undergraduate students, faculty, and the public in the Intermountain West. METHODS Surveys were administered before and after a staged reading of the play by professional actors. Survey items included the short form Trust in Medical Researchers, and single-item questions about group identity, ethics of genetic testing in children, and willingness to donate biospecimens. In addition, respondents were given the option to answer open-ended questions through e-mail. RESULTS Out of the 481 who attended the play, 421 completed both the pre and post surveys, and 166 participants completed open-ended questions online approximately 1 week after the play. Across all participants, there were significant declines for trust in medical researchers and for the survey item "is it ethical for investigators to test children for adult onset diseases" (p < .001 for both) following the play. There was a significant increase in agreement to improve group identity protections (p < .001) and there were no differences on willingness to donate biospecimens to research (p = .777). Qualitative data provided extensive contextual data supporting these perspectives. DISCUSSION This is one of the first studies to document short-term impacts of a theatrical performance on both attitudes and behavioral intentions toward research ethics and clinical research participation. Future research should continue to explore the impact of theatrical performances among public and investigators on the ethical issues and complexities in clinical research.
Collapse
Affiliation(s)
| | | | | | - Bob Wong
- a University of Utah , Salt Lake City , Utah , USA
| | | | - Erin Johnson
- a University of Utah , Salt Lake City , Utah , USA
| | | | - Alena Wilson
- a University of Utah , Salt Lake City , Utah , USA
| | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- Darla R Shores
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD.
| | - Allen D Everett
- Division of Cardiology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD
| |
Collapse
|
31
|
Bourgeois FT, Avillach P, Kong SW, Heinz MM, Tran TA, Chakrabarty R, Bickel J, Sliz P, Borglund EM, Kornetsky S, Mandl KD. Development of the Precision Link Biobank at Boston Children's Hospital: Challenges and Opportunities. J Pers Med 2017; 7:E21. [PMID: 29244735 DOI: 10.3390/jpm7040021] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Revised: 11/30/2017] [Accepted: 12/12/2017] [Indexed: 11/24/2022] Open
Abstract
Increasingly, biobanks are being developed to support organized collections of biological specimens and associated clinical information on broadly consented, diverse patient populations. We describe the implementation of a pediatric biobank, comprised of a fully-informed patient cohort linking specimens to phenotypic data derived from electronic health records (EHR). The Biobank was launched after multiple stakeholders’ input and implemented initially in a pilot phase before hospital-wide expansion in 2016. In-person informed consent is obtained from all participants enrolling in the Biobank and provides permission to: (1) access EHR data for research; (2) collect and use residual specimens produced as by-products of routine care; and (3) share de-identified data and specimens outside of the institution. Participants are recruited throughout the hospital, across diverse clinical settings. We have enrolled 4900 patients to date, and 41% of these have an associated blood sample for DNA processing. Current efforts are focused on aligning the Biobank with other ongoing research efforts at our institution and extending our electronic consenting system to support remote enrollment. A number of pediatric-specific challenges and opportunities is reviewed, including the need to re-consent patients when they reach 18 years of age, the ability to enroll family members accompanying patients and alignment with disease-specific research efforts at our institution and other pediatric centers to increase cohort sizes, particularly for rare diseases.
Collapse
|
32
|
Ostrom QT, Devine K, Fulop J, Wolinsky Y, Liao P, Stetson L, Couce M, Sloan AE, Barnholtz-Sloan JS. Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology. Neurooncol Pract 2017; 4:220-228. [PMID: 29692920 PMCID: PMC5909804 DOI: 10.1093/nop/npw029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The growth of precision medicine has made access to biobanks with high-quality, well-annotated neuro-oncology biospecimens critical. Developing and maintaining neuro-oncology biobanks is best accomplished through multidisciplinary collaboration between clinicians and researchers. Balancing the needs and leveraging the skills of all stakeholders in this multidisciplinary effort is of utmost importance. Collaboration with a multidisciplinary team of clinicians, health care team members, and institutions, as well as patients and their families, is essential for access to participants in order to obtain informed consent, collect samples under strict standard operating procedures, and accurate and relevant clinical annotation. Once a neuro-oncology biobank is established, development and implementation of policies related to governance and distribution of biospecimens (both within and outside the institution) is of critical importance for sustainability. Proper implementation of a governance process helps to ensure that the biospecimens and data can be utilized in research with the largest potential benefit. New NIH and peer-reviewed journal policies related to public sharing of 'omic' data generated from stored biospecimens create new ethical challenges that must be addressed in developing informed consents, protocols, and standard operating procedures. In addition, diversification of sources of funding for the biobanks is needed for long-term sustainability.
Collapse
Affiliation(s)
- Quinn T Ostrom
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Karen Devine
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Jordonna Fulop
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Yingli Wolinsky
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Peter Liao
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Lindsay Stetson
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Marta Couce
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Andrew E Sloan
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| | - Jill S Barnholtz-Sloan
- Case Comprehensive Cancer Center, Wearn 152, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio 44106 (Q.T.O., K.D., J.F., P.L., L.S., A.E.S., J.S.B.S.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2103 Cornell Rd, WRB 2-532, Cleveland, Ohio 44106-7295 (Y.W.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio 44106 (M.C.); Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, 11100 Euclid Ave, Cleveland, Ohio 44106 (A.E.S., J.S.B.S.)
| |
Collapse
|
33
|
Rivera SM, Nichols L, Brako L, Croft G, Russo T, Tran T. CTSA Institution Responses to Proposed Common Rule Changes: Did They Get What They Wanted? J Empir Res Hum Res Ethics 2017; 12:79-86. [PMID: 28421883 DOI: 10.1177/1556264617698606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In 2015, the U.S. Department of Health and Human Services (HHS) and 15 other federal departments and agencies proposed revisions to the Federal Policy for the Protection of Human Subjects. In this Notice of Proposed Rulemaking (NPRM), the departments sought to strengthen, modernize, and make more effective human subjects regulations while reducing administrative burden, delay, and ambiguity. We reviewed public comments from National Institutes of Health (NIH)-funded Clinical and Translational Science Awards (CTSA) institutions on key provisions of the NPRM to understand how the proposed changed were received at research-intensive institutions. CTSA institutions responding to the proposed rule were predominantly opposed to the major proposals, including proposed changes to the treatment of de-identified biospecimens, demonstrating a lack of support from academic medical centers. In January 2017, a Final Rule was issued. We compare the Final Rule to what was proposed.
Collapse
Affiliation(s)
| | - Lisa Nichols
- 2 Council on Governmental Relations, Washington, DC, USA
| | - Lois Brako
- 3 University of Michigan, Ann Arbor, USA
| | - Genevieve Croft
- 4 Association of Public & Land-grant Universities, Washington, DC, USA
| | - Toni Russo
- 2 Council on Governmental Relations, Washington, DC, USA
| | - Tara Tran
- 1 Case Western Reserve University, Cleveland, OH, USA
| |
Collapse
|
34
|
Engel LS, Kwok RK, Miller AK, Blair A, Curry MD, McGrath JA, Sandler DP, Baker S, Cohn RD, Gaunt EE, Hodges A, Johndrow D, Ramsey SK, Stenzel M, Stewart P. The Gulf Long-Term Follow-Up Study (GuLF STUDY): Biospecimen collection at enrollment. J Toxicol Environ Health A 2017; 80:218-229. [PMID: 28418274 PMCID: PMC5522735 DOI: 10.1080/15287394.2017.1283274] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The 2010 Deepwater Horizon (DWH) explosion in the Gulf of Mexico led to the largest ever marine oil spill by volume. The GuLF STUDY is investigating possible adverse human health effects associated with oil spill activities. One objective of the study was to utilize biological specimens from study participants to examine spill-related adverse health effects. This study describes the methods for collecting, processing, shipping, and storing specimens during the enrollment phase of the study. GuLF STUDY participants living in Gulf States (Alabama, Florida, Louisiana, Mississippi, and eastern Texas) were eligible to complete a home visit at enrollment, one to three years after the DWH explosion. During this visit, blood, urine, toenail and hair clippings, and house dust samples were collected. Specimens were shipped overnight to a central processing laboratory in containers with cold and ambient temperature compartments. Most blood and urine specimens were then aliquoted and stored in liquid nitrogen vapor or at -80°C, with some samples stored at -20°C. A total of 11,193 participants completed a home visit, and over 99% provided at least one biospecimen. Most participants provided blood (93%), urine (99%), and toenail clippings (89%), and 40% provided hair. Nearly all participants (95%) provided house-dust samples. Most samples were received by the laboratory one (58%) or two (25%) days after collection. These biospecimens enable investigation of a range of biomarkers of spill-related adverse health effects, and possibly some biomarkers of spill-related exposures. The biospecimen collection, handling, and storage protocols were designed to maximize current and future scientific value within logistical and budgetary constraints and might serve as a template for future studies conducted in similar time-critical and geographically dispersed settings.
Collapse
Affiliation(s)
- Lawrence S. Engel
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | - Richard K. Kwok
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | - Aubrey K. Miller
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | - Aaron Blair
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
| | | | - John A. McGrath
- Social & Scientific Systems, Inc., Durham, North Carolina, USA
| | - Dale P. Sandler
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | | | - Susan Baker
- Social & Scientific Systems, Inc., Durham, North Carolina, USA
| | - Richard D. Cohn
- Social & Scientific Systems, Inc., Durham, North Carolina, USA
| | - Edward E. Gaunt
- Social & Scientific Systems, Inc., Durham, North Carolina, USA
| | - Audra Hodges
- Social & Scientific Systems, Inc., Durham, North Carolina, USA
| | - David Johndrow
- Social & Scientific Systems, Inc., Durham, North Carolina, USA
| | | | - Mark Stenzel
- Exposure Assessment Applications LLC, Arlington, Virginia, USA
| | | |
Collapse
|
35
|
Abstract
BACKGROUND There is a growing number of cohorts and registries collecting phenotypic and genotypic data from groups of multiple sclerosis patients. Improved awareness and better coordination of these efforts is needed. OBJECTIVE The purpose of this report is to provide a global landscape of the major longitudinal MS patient data collection efforts and share recommendations for increasing their impact. METHODS A workshop that included over 50 MS research and clinical experts from both academia and industry was convened to evaluate how current and future MS cohorts could be better used to provide answers to urgent questions about progressive MS. RESULTS The landscape analysis revealed a significant number of largely uncoordinated parallel studies. Strategic oversight and direction is needed to streamline and leverage existing and future efforts. A number of recommendations for enhancing these efforts were developed. CONCLUSIONS Better coordination, increased leverage of evolving technology, cohort designs that focus on the most important unanswered questions, improved access, and more sustained funding will be needed to close the gaps in our understanding of progressive MS and accelerate the development of effective therapies.
Collapse
Affiliation(s)
- Bruce F Bebo
- National Multiple Sclerosis Society, New York, NY, USA
| | - Robert J Fox
- Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA
| | - Karen Lee
- Multiple Sclerosis Society of Canada, Toronto, ON, Canada
| | - Ursula Utz
- Division of Extramural Research, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD, USA
| | - Alan J Thompson
- Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
| |
Collapse
|
36
|
Abstract
In September, the U.S. Department of Health and Human Services, together with other federal agencies, announced proposed changes to the rules governing human subjects research. This Commentary discusses how the proposals would affect research using biospecimens that is essential to the future success of precision medicine. We argue that the proposed changes unnecessarily burden such research, without meaningfully advancing the interests of donors. They should be revised before being finalized.
Collapse
Affiliation(s)
- Christopher T Robertson
- James E. Rogers College of Law and Arizona Health Sciences Center Regulatory Science Program, University of Arizona , Tucson, Arizona
| | - Jonathan D Loe
- James E. Rogers College of Law and Arizona Health Sciences Center Regulatory Science Program, University of Arizona , Tucson, Arizona
| |
Collapse
|
37
|
Abstract
There are several aspects to a histopathology practice besides the acquisition of biopsy specimens and histopathological diagnosis. Pathology Departments are home to an abundant source of knowledge in the form of stored specimens and slides. We attempt to highlight the importance of regulation of storage, retention, and appropriate use of human tissue material in research and ownership rights to the same. We also discuss requirement and waiver of informed consent for scientific work involving the use of such tissues, which in the absence of defined laws come under the purview of Institution Review Boards. Pathology Departments, under the binding of the parent institution, are conceded the responsibility of maintenance and retention of pathology specimens. This communication highlights some of the important aspects in human tissue material handling and research, underscoring the necessity for established regulations regarding the same.
Collapse
Affiliation(s)
- Supriya Nikita Kapila
- Department of Oral Pathology and Microbiology, Manipal College of Dental Sciences, Manipal University, Mangalore, Karnataka, India
| | - Karen Boaz
- Department of Oral Pathology and Microbiology, Manipal College of Dental Sciences, Manipal University, Mangalore, Karnataka, India
| | - Srikant Natarajan
- Department of Oral Pathology and Microbiology, Manipal College of Dental Sciences, Manipal University, Mangalore, Karnataka, India
| |
Collapse
|
38
|
Hassona Y, Ahram M, Odeh N, Abu Gosh M, Scully C. Factors Influencing Dental Patient Participation in Biobanking and Biomedical Research. Med Princ Pract 2016; 25:323-8. [PMID: 27165114 PMCID: PMC5588431 DOI: 10.1159/000446479] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 04/27/2016] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVES To study the willingness of dental patients to donate biospecimens for research purpose and to examine factors that may influence such a decision. MATERIALS AND METHODS A face-to-face interview was conducted using a pretested structured survey instrument on 408 adult dental patients attending a university hospital for dental care. Descriptive statistics were generated, and the x03C7;2 test was used to examine differences between groups. p values ≤0.5 were considered statistically significant. RESULTS Of the 408 participants, only 71 (17.4%) had heard of the terms biobanking/biospecimens, but 293 (71.9%) approved of the idea of using biospecimens for biomedical research, and 228 (55.9%) were willing to donate biospecimens and give personal information for research purposes. In participants who were unwilling to participate in biobanking, fear of information leakage was the most frequently reported reason, while in participants who were willing to donate biospecimens, the potential to provide more effective and less costly treatments was the most frequently reported reason. The preferences of the 228 participants who were willing to donate biospecimens were as follows: give a sample of removed oral tissues including extracted teeth (n = 105, 46.1%), donate a blood sample (n = 52, 23%), donate a sample of saliva (n = 43, 18.6%), and give a urine sample (n = 28, 12.3%). CONCLUSION Dental patients had a generally positive attitude towards biomedical research and biobanking. The most preferred types of biospecimens to donate in a dental setting were removed tissues, including extracted teeth and blood samples.
Collapse
Affiliation(s)
- Yazan Hassona
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, London, UK
- *Yazan Hassona, Departments of Oral and Maxillofacial Surgery, Faculty of Dentistry, The University of Jordan, Queen Rania Street, PO Box 11942, Amman (Jordan), E-Mail
| | - Mamoun Ahram
- Department of Physiology and Biochemistry, Faculty of Medicine, The University of Jordan, Amman, Jordan
| | - Noorah Odeh
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, London, UK
| | - Mais Abu Gosh
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, London, UK
| | - Crispian Scully
- World Health Organization Collaborating Centre on Oral Health, University College London, London, UK
| |
Collapse
|
39
|
Rivera SM, Goldenberg A, Rosenthal B, Aungst H, Maschke KJ, Rothwell E, Anderson RA, Botkin J, Joffe S. Investigator Experiences and Attitudes About Research With Biospecimens. J Empir Res Hum Res Ethics 2015; 10:449-56. [PMID: 26564943 PMCID: PMC4646730 DOI: 10.1177/1556264615610199] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
To advance scientific knowledge about human diseases and effective therapeutic treatments, investigators need access to human biospecimens and associated data. However, regulatory and procedural requirements may impede investigators' efforts to share biospecimens and data within and across institutions. Although a number of studies have explored experiences and attitudes of study participants and others about biospecimen and data sharing, less is known about investigators' perspectives. We conducted an electronic survey to learn about investigators' experiences and attitudes about research with biospecimens and associated data. A total of 114 practicing scientists from a pool of 60 university medical schools with Clinical and Translational Science Awards (CTSAs) funded by the National Institutes of Health (NIH) participated. We found a high degree of variability in investigators' experiences with institutional review boards (IRBs) when seeking approval to conduct biospecimen research, as well as differences in approaches to informed consent for the collection of specimens. Participants also expressed concerns that the risks of biospecimen research may be overestimated by IRBs. This research suggests that the current regulatory environment for human research protections may require reconsideration with regard to standards for collection, use, and sharing of biospecimens and data.
Collapse
Affiliation(s)
| | | | | | - Heide Aungst
- Case Western Reserve University, Cleveland, OH, USA
| | | | | | | | | | | |
Collapse
|
40
|
Abdul-Rahman OA, Rodriguez B, Wadlinger SR, Slutsman J, Boyle EB, Merrill LS, Botkin J, Moye J. Success rates for consent and collection of prenatal biological specimens in an epidemiologic survey of child health. ACTA ACUST UNITED AC 2015; 106:47-54. [PMID: 26407522 DOI: 10.1002/bdra.23455] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The National Children's Study (NCS) Vanguard Study began enrollment in January 2009 as an initial pilot study for a planned large-scale, longitudinal U.S. cohort study of the effect of environmental influences on child health and development, with biological and environmental sample collection conducted in seven locations from April 2009 to October 2010. We sought to determine rates of consent for, and success of collection of, maternal and paternal biospecimens before and during pregnancy in the NCS Vanguard Study. METHODS Samples of blood, saliva, vaginal swabs, urine, hair, and nails were collected before and during pregnancy. All specimens were sent to a central repository for processing, storage, and quality assessment. RESULTS Of 780 pregnant women asked to consent to sample collection, 773 (>99%) agreed, and of 295 nonpregnant women, 292 (99%) agreed. Of 440 fathers asked to consent to sample collection, 435 (99%) agreed. Frequency of successful collection of biospecimens varied depending on sample and visit type. In descending order, the ranges over all visit types of the proportion of expected samples successfully collected from women were: urine, 92.5 to 95.7%; hair, 89.6 to 92.5%; vaginal swab, 84.2 to 88.5%; blood, 74.9 to 78.5%; 2-day saliva, 65.8 to 81.6%; and nails, 76.4 to 76.7%. For fathers, rates were highest for urine (94.9%) and lowest for hair (63.0%). CONCLUSION High rates of consent for and collection of a wide variety of biospecimens can be achieved in prospective epidemiologic cohort studies of pregnant women. Ease of sample collection may be a primary factor influencing successful biospecimen collection.
Collapse
Affiliation(s)
- Omar A Abdul-Rahman
- Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi
| | | | | | - Julia Slutsman
- National Children's Study Program Office, NICHD, NIH, Bethesda, Maryland
| | | | | | | | - Jack Moye
- National Children's Study Program Office, NICHD, NIH, Bethesda, Maryland
| |
Collapse
|
41
|
Cadigan RJ, Nelson DK, Henderson GE, Nelson AG, Davis AM. Public Comments on Proposed Regulatory Reforms That Would Impact Biospecimen Research: The Good, the Bad, and the Puzzling. IRB 2015; 37:1-10. [PMID: 26523321 PMCID: PMC6763272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The regulations governing human subjects research (45 CFR 46) remain largely unchanged since their adoption. As a first step in their revision, the federal government published the Advance Notice of Proposed Rule Making (ANPRM) in 2011. The public responded with over 1100 comments. We selected a random sample of 300 comments, examining whether they addressed biospecimen research in terms of views on mandated consent, waivers of consent, use of a short general consent form, or identifiability of biospecimens. We conducted content analysis on the 109 comments that fulfilled these criteria Findings reveal little support for the proposal to mandate consent, strong support for the current waiver system, confusion about use of a standard general consent form, and disagreement about the implications of biospecimen identifiability. As the government moves ahead in its rulemaking process, it is important to consider what the public comments reveal about support and/or concerns for proposed changes.
Collapse
|
42
|
Barker AD, Compton CC, Poste G. The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic. Biomark Med 2015; 8:873-6. [PMID: 25224942 DOI: 10.2217/bmm.14.52] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Anna D Barker
- Complex Adaptive Systems, National Biomarker Development Alliance (NBDA), Arizona State University, SkySong, 1475 N. Scottsdale Rd, Suite 361, Scottsdale, AZ 85257, USA
| | | | | |
Collapse
|
43
|
Goldenberg AJ, Maschke KJ, Joffe S, Botkin JR, Rothwell E, Murray TH, Anderson R, Deming N, Rosenthal BF, Rivera SM. IRB practices and policies regarding the secondary research use of biospecimens. BMC Med Ethics 2015; 16:32. [PMID: 25953109 PMCID: PMC4426182 DOI: 10.1186/s12910-015-0020-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Accepted: 04/23/2015] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND As sharing and secondary research use of biospecimens increases, IRBs and researchers face the challenge of protecting and respecting donors without comprehensive regulations addressing the human subject protection issues posed by biobanking. Variation in IRB biobanking policies about these issues has not been well documented. METHODS This paper reports on data from a survey of IRB Administrative Directors from 60 institutions affiliated with the Clinical and Translation Science Awards (CTSAs) about their policies and practices regarding secondary use and sharing of biospecimens. Specifically, IRB ADs were asked about consent for future use of biospecimens, assignment of risk for studies using biobanked specimens, and sharing of biospecimens/data. RESULTS Our data indicate that IRBs take varying approaches to protocol review, risk assessment, and data sharing, especially when specimens are not anonymized. CONCLUSION Unclear or divergent policies regarding biospecimen research among IRBs may constitute a barrier to advancing genetic studies and to inter-institutional collaboration, given different institutional requirements for human subjects protections.
Collapse
Affiliation(s)
- Aaron J Goldenberg
- Department of Bioethics, TA212 School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106, USA.
| | - Karen J Maschke
- The Hastings Center and the Centre for Biomedical Ethics, Garrison, New York, USA.
| | - Steven Joffe
- Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
| | - Jeffrey R Botkin
- Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
| | - Erin Rothwell
- Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
| | - Thomas H Murray
- The Hastings Center and the Centre for Biomedical Ethics, Garrison, New York, USA.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
| | - Rebecca Anderson
- Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
| | - Nicole Deming
- Department of Bioethics, TA212 School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106, USA.
| | - Beth F Rosenthal
- Department of Bioethics, TA212 School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106, USA.
| | - Suzanne M Rivera
- Department of Bioethics, TA212 School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106, USA.
| |
Collapse
|
44
|
Poste G, Compton CC, Barker AD. The national biomarker development alliance: confronting the poor productivity of biomarker research and development. Expert Rev Mol Diagn 2014; 15:211-8. [PMID: 25420639 DOI: 10.1586/14737159.2015.974561] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Making precision (personalized) medicine a routine clinical reality will require a comprehensive inventory of validated biomarkers and molecular diagnostic tests to stratify disease subtypes and improve accuracy in diagnosis and treatment selection. Realization of this promise has been hindered by the poor productivity of biomarker identification and validation. This situation reflects deficiencies that are pervasive across the entire spectrum of biomarker R&D, from discovery to clinical validation and in the failure of regulatory and reimbursement policies to accommodate new classes of biomarkers. The launch of the National Biomarker Development Alliance is the culmination of a 2-year review and consultation process involving diverse stakeholders to advance standards, best practices and guidelines to enhance biomarker discovery and validation by adoption of systems-based approaches and trans-sector collaboration between academia, clinical medicine and relevant private and public sector stakeholders.
Collapse
Affiliation(s)
- George Poste
- NBDA, Arizona State University, SkySong, 1475 N. Scottsdale Rd., Suite 361, Scottsdale, AZ 85257, USA
| | | | | |
Collapse
|
45
|
Dang JHT, Rodriguez EM, Luque JS, Erwin DO, Meade CD, Chen MS. Engaging diverse populations about biospecimen donation for cancer research. J Community Genet 2014; 5:313-27. [PMID: 24664489 PMCID: PMC4159470 DOI: 10.1007/s12687-014-0186-0] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Accepted: 03/10/2014] [Indexed: 01/14/2023] Open
Abstract
Clinical research increasingly relies upon the availability of appropriate genetic materials; however, the proportion of biospecimens from racial/ethnic minority patients and healthy controls are underrepresented, which preclude equitable research across all patient groups for cancer treatment. National Cancer Institute-funded Community Network Program Centers in California, Florida, and New York collaborated with local community partners to conduct three independent formative research studies with diverse (African American, Asian American, Hispanic, and White) participants to explore their knowledge, attitudes, and beliefs about biobanking, and their experiences with the donation of biospecimens. Our findings demonstrated similarities in overall low knowledge and understanding about the use of biospecimens for research. This was exacerbated for non-English speakers. Racial and ethnic groups differed with regard to a number of factors that are obstacles for participation, e.g., continuing medical mistrust (African Americans), lack of benefit (Hispanics), apprehension about the physical toll of donating (Vietnamese), usage of biospecimen for research (Hmong and Chinese), and suspicion of exploitation by corporate entities (Whites). However, participants uniformly reported general interest and willingness to participate in biobanking for altruistic purposes, particularly to benefit future generations. This interest was framed with a strong admonition that donations should be accompanied by transparency about study sponsorship and ownership, distribution and use of biospecimens, and study information that fit participants' backgrounds and experiences. This cross-cultural regional analysis offers significant insights into the similarities and variations in opinions and perceptions about biobanking and the collection of biospecimens for use in cancer research.
Collapse
Affiliation(s)
- Julie H. T. Dang
- />UC Davis Comprehensive Cancer Center, 4800 2nd Avenue, FSSB, Suite 2200, Sacramento, CA 95817 USA
| | - Elisa M. Rodriguez
- />Cancer Prevention and Population Sciences, Center for Personalized Medicine, Rosewell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263 USA
| | - John S. Luque
- />Jiann-Ping Hsu College of Public Health, Georgia Southern University, PO Box 8015, Statesboro, GA 30460 USA
| | - Deborah O. Erwin
- />Cancer Prevention and Population Sciences, Rosewell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263 USA
| | - Cathy D. Meade
- />Division of Population Science, Health Outcomes & Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612 USA
| | - Moon S. Chen
- />UC Davis Comprehensive Cancer Center, 4800 2nd Avenue, FSSB, Suite 2200, Sacramento, CA 95817 USA
| |
Collapse
|
46
|
Abstract
The disparities in prostate cancer incidence and mortality continue to be a global public health problem. Efforts to address the prostate cancer disparity in black men have been met with a number of challenges, specifically in the accessibility to biospecimens in the context of global prostate cancer collaborations. During the International Educational Workshop at the Science of Global Prostate Cancer Disparities conference held 1–4 November 2012 in Nassau, the Bahamas, an overview of biobanking and biospecimen repositories, and materials transfer in global prostate cancer collaborations were discussed. The challenges faced by low-resource countries were identified, and potential solutions were recommended.
Collapse
Affiliation(s)
- Camille Ragin
- Cancer Prevention and Control Programme, Fox Chase Cancer Centre, Temple University Health System, 333 Cottman Avenue, Philadelphia, PA 19111, USA ; African Caribbean Cancer Consortium (AC3)
| | - Jong Y Park
- African Caribbean Cancer Consortium (AC3) ; Department of Cancer Epidemiology, Moffitt Cancer Centre, Tampa, FL 33612, USA ; Prostate Cancer Transatlantic Consortium (CaPTC)
| |
Collapse
|
47
|
Schwiebert LM, Estell K, Meadows T, Thannickal VJ, Rowe S, Sorscher EJ, Harris WT, Gaggar A, Dransfield M, de Andrade JA. Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients. Clin Transl Sci 2014; 7:336-41. [PMID: 24889057 DOI: 10.1111/cts.12161] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
The Pulmonary Biospecimen Repository (PBR) at the University of Alabama at Birmingham (UAB) was launched in 2009. The purpose of the UAB PBR is to provide investigators within the pulmonary community at UAB and elsewhere with clinical samples derived from multiple lung diseases, including transplant recipients, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Cell and fluid samples isolated from bronchoalveolar lavage (BAL), plasma, and serum are collected and stored; samples are assessed routinely for viability. Each sample is linked directly with the respective patient information via the Pulmonary Translational Research and Clinical Database, a Health Insurance Portability and Accountability Act compliant database that includes detailed information allowing for the study of specific patient cohorts. To access samples, investigators must complete a request form, which is reviewed by the UAB PBR Steering Committee. To date, more than 800 patients have provided approximately 7,000 BAL, serum and plasma fluid, and cell samples. Over the past 4 years, nearly 800 of these samples have been distributed to investigators at UAB and elsewhere. Future plans for the UAB PBR include expanding sample collection to additional pulmonary diseases, such as mycobacterial infections, increasing the number of sample users and obtaining external funding to ensure its continued sustainability.
Collapse
Affiliation(s)
- Lisa M Schwiebert
- Department of Cell, Developmental and Integrative Biology; Department of Medicine - Division of Pulmonary, Allergy and Critical Care Medicine
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Botkin JR, Anderson R, Murray T, Beskow LM, Maschke K, Cuttler L. Proposed regulations for research with biospecimens: responses from stakeholders at CTSA consortium institutions. Am J Med Genet A 2014; 164A:892-7. [PMID: 24459038 DOI: 10.1002/ajmg.a.36365] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 10/20/2013] [Indexed: 01/07/2023]
Abstract
Secondary research with biospecimens acquired through clinical care and through research is often conducted without the informed consent of individuals from whom the specimens were acquired. While such uses are consistent with the current federal regulations, surveys of the general public suggest that many individuals would prefer more information and choice regarding research use of biospecimens. The federal government issued an Advance Notice of Proposed Rulemaking (ANPRM) in 2011 that proposed a number of potential changes in the regulations governing human subjects. These proposed regulations are particularly pertinent to institutions committed to research involving human subjects-including institutions in the NIH-funded Clinical and Translational Science Awards (CTSA) consortium. In this study, we reviewed public responses by CTSA-funded institutions and CTSA-affiliated organizations and groups regarding the proposed changes in the ANPRM with respect to research with biospecimens. Our results indicate that the majority of responses to the ANPRM from CTSA institutions were not supportive of the proposed changes. While many responses acknowledge a need to change current research practices regarding biospecimens, the proposed changes in the ANPRM received only limited support from this subgroup of academic research institutions.
Collapse
Affiliation(s)
- Jeffrey R Botkin
- Department of Pediatrics, University of Utah, Salt Lake City, Utah
| | | | | | | | | | | |
Collapse
|
49
|
Mora E, Robb JA, Stefanoff G, Mellado RH, Coppola D, Muñoz-Antonia T, Flores I. Proceedings of the 1st Puerto Rico Biobanking Workshop. Rev Recent Clin Trials 2014; 9:233-44. [PMID: 25626063 PMCID: PMC4635463 DOI: 10.2174/1574887110666150127105545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 12/02/2014] [Accepted: 12/08/2014] [Indexed: 05/02/2023]
Abstract
The 1st Puerto Rico Biobanking Workshop took place on August 20st, 2014 in the Auditorium of the Comprehensive Cancer Center of the University of Puerto Rico, Medical Sciences Campus in San Juan Puerto Rico. The program for this 1-day, live workshop included lectures by three biobanking experts, followed by presentations from existing biobanks in Puerto Rico and audience discussion. The need for increasing biobanking expertise in Puerto Rico stems from the fact that Hispanics in general are underrepresented in the biobanks in existence in the US, which limits the research conducted specifically to understand the molecular differences in cancer cells compared to other better studied populations. In turn, this lack of information impairs the development of better diagnostic and therapeutic approaches for our population. Dr. James Robb, M.D., F.C.A.P., consulting pathologist to the National Cancer Institute (NCI) and the Office of Biorepositories and Biospecimen Research (OBBR), opened the workshop with a discussion on the basic aspects of the science of biobanking (e.g., what is a biobank; its goals and objectives; protocols and procedures) in his talk addressing the importance of banking tissues for advancing biomedical research. Next, Dr. Gustavo Stefanoff, from the Cancer Institutes Network of Latin America (RINC by its name in Spanish), explained the mission, objectives, and structure of the Network of Latin-American and Caribbean Biobanks (REBLAC by its name in Spanish), which despite limited resources and many challenges, currently accrue high quality human tissue specimens and data to support cancer research in the region. Dr. Robert Hunter-Mellado, Professor of Internal Medicine, Universidad Central del Caribe, followed with an examination of the ethical and regulatory aspects of biobanking tissues for future research, including informed consent of subjects; protection of human subjects rights; and balancing risks and benefit ratios. In the afternoon, the directors of existing biobanks in Puerto Rico (the Puerto Rico Biobank, the Comprehensive Cancer Center biobank, and an HIV-focused biobank at Universidad Central del Caribe) presented their experiences and challenges with establishing biobanks for research in Puerto Rico. In sum, this workshop presented opportunities to share knowledge in the science of biobanking, for further training, and of networking among the participants (34 from 4 different institutions), which will strengthen the collaborative links between investigators studying cancer in Latin America, the Caribbean, and the US.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Idhaliz Flores
- Department of Microbiology, Department of Ob-Gyn, Ponce Health Sciences University & School of Medicine, Ponce Research Institute, PO BOX 7004, Ponce, PR 00732.
| |
Collapse
|
50
|
Kang B, Park J, Cho S, Lee M, Kim N, Min H, Lee S, Park O, Han B. Current status, challenges, policies, and bioethics of biobanks. Genomics Inform 2013; 11:211-7. [PMID: 24465232 PMCID: PMC3897848 DOI: 10.5808/gi.2013.11.4.211] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 11/07/2013] [Accepted: 11/13/2013] [Indexed: 12/30/2022] Open
Abstract
Many biobanks were established as biorepositories for biomedical research, and a number of biobanks were founded in the 1990s. The main aim of the biobank is to store and to maintain biomaterials for studying chronic disease, identifying risk factors of specific diseases, and applying personalized drug therapies. This report provides a review of biobanks, including Korean biobanks and an analysis of sample volumes, regulations, policies, and ethical issues of the biobank. Until now, the top 6 countries according to the number of large-scale biobanks are the United Kingdom, United States, Sweden, France, the Netherlands, and Italy, and there is one major National Biobank of Korea (NBK) and 17 regional biobanks in Korea. Many countries have regulations and guidelines for the biobanks, and the importance of good management of biobanks is increasing. Meanwhile, according to a first survey of 456 biobank managers in the United States, biobankers are concerned with the underuse of the samples in their repositories, which need to be advertised for researchers. Korea Biobank Network (KBN) project phase II (2013-2015) was also planned for the promotion to use biospecimens in the KBN. The KBN is continuously introducing for researchers to use biospecimens in the biobank. An accreditation process can also be introduced for biobanks to harmonize collections and encourage use of biospecimens in the biobanks. KBN is preparing an on-line application system for the distribution of biospecimens and a biobank accreditation program and is trying to harmonize the biobanks.
Collapse
Affiliation(s)
- Byunghak Kang
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Jaesun Park
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Sangyun Cho
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Meehee Lee
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Namhee Kim
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Haesook Min
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Sooyoun Lee
- Division of Biobank for Health Sciences, Korea National Institute of Health, Cheongwon 363-951, Korea
| | - Ok Park
- Division of Vaccine Preventable Diseases, Korea Centers for Disease Control and Prevention, Cheongwon 363-951, Korea
| | - Bokghee Han
- Center for Genome Science, Korea National Institute of Health, Cheongwon 363-951, Korea
| |
Collapse
|